ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home PD-L1

Gemcitabine: A New Chemotherapy Partner for Immune Checkpoint Inhibitors? Insights From the ORIENT-12 Study

Chunxia Su
on: August 27, 2021In: Evolving Standards of Care
Gemcitabine: A New Chemotherapy Partner for Immune Checkpoint Inhibitors? Insights From the ORIENT-12
            Study

Squamous cell lung cancer (SqCLC), which accounts for approximately 25% to 30% of all lung cancer cases, is the second-most prevalent histologic subtype of NSCLC. Its distinct clinicopathologic and molecular […] Read more


Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade

on: April 15, 2020In: Evolving Standards of Care
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade

By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field […] Read more

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

on: April 15, 2020In: Diagnostic Oncology
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more

CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC

on: February 11, 2020In: Evolving Standards of Care
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC

By Neal Ready, MD, PhD Posted: February 12, 2020 Dr. Neal Ready Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of advanced […] Read more

PD-L1 in Cytology Specimens

on: December 10, 2019In: Diagnostic Oncology
PD-L1 in Cytology Specimens

By Anjali Saqi, MD, MBA; Deepali Jain, MD, FIAC; Lukas Bubendorf, MD; Keith Kerr, MB, ChB, MRCPath, FRCPath, FRCP(Ed); and Andre Moreira, MD, PhD Posted: December 11, 2019 Lung cancer […] Read more

Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data

on: December 10, 2019In: Evolving Standards of Care
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational
            Data

Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. […] Read more

Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization

on: November 11, 2019In: Diagnostic Oncology
Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization

By Mari Mino-Kenudson, MD, and Sylvie Lantuejoul, MD, PhD Posted: November 12, 2019 Determination of PD-L1 expression by immunohistochemistry (IHC) has been widely evaluated in clinical trials as a predictive […] Read more

IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy